Related Experiment Video
Updated: Feb 3, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Clinical Diversity in Patients with Anderson-fabry Disease with the R301Q Mutation
Saori Yamamoto1, Tasuku Nagasawa2, Koichiro Sugimura1
1Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Japan.
Abstract:
Anderson-Fabry disease (AFD) is a rare X-linked disorder caused by deficient activity of the lysosomal enzyme α-galactosidase A (α-GAL A). We herein report 10 cases of AFD in 5 families (3 men and 7 women) that were found to have a specific common mutation in R301Q [G-to-A transition in exon 6 (codon 301) resulting in the replacement of a glutamine with an arginine residue]. We evaluated their clinical characteristics, residual enzymatic activity, and plasma concentrations of globotriaosylsphingosine (Lyso-Gb3). Although all 10 cases had cardiac and renal manifestations in common, their clinical manifestations were markedly divergent despite the same genetic abnormality.
Related Concept Videos
The Anderson-Darling Test
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Chronic Kidney Disease II: Clinical Manifestations
Viral Mutations
Coronary Artery Disease III: Clinical Manifestations

